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Abstract
Cardiovascular malformations (CVMs) are the most common birth defect, occurring in 1–5% of 
all live births. Genetic, epigenetic, and environmental factors all influence the development of 
CVMs, and an improved understanding of causation of CVMs is a prerequisite for prevention. 
Cardiac development is a complex, multi-step process of morphogenesis that is under genetic 
regulation. Multiple developmental pathways act independently or in combination to effect proper 
cardiac lineage specification, differentiation, and structure. Because of this complexity, there are 
numerous potential mechanisms by which genetic variation can impact both fetal cardiac 
development and latent cardiac disease. Although the genetic contribution to CVMs is well 
recognized, the genetic causes of human CVMs are still identified relatively infrequently. Mouse 
models are important tools to investigate the molecular mechanisms underpinning cardiac 
development as well as the complex genetics that characterize human CVMs. In this review we 
provide an overview of the key genetic concepts characterizing human CVMs, review their 
developmental basis, and provide examples to illustrate the critical developmental and genetic 
concepts underlying the pathogenesis of CVMs.
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INTRODUCTION
The underlying causes of CVMs can include cytogenetic abnormalities, single gene 
disorders, environmental etiologies, or most commonly, multifactorial etiologies (Table 1). 
Chromosomal abnormalities account for 12–14% of all live born cases and 20–33% of fetal 
cases of congenital cardiovascular malformations (CVMs), indicating that the proper genetic 
control of cardiac development is essential 1–4. CVMs can occur as isolated findings, as part 
of a well-defined syndrome, or in conjunction with additional extracardiac anomalies not 
formally recognized as a syndrome 5. The designation of CVMs as isolated can be 
problematic since many important distinguishing features of syndromic conditions, such as 
developmental delay or dysmorphic features, may not be apparent at initial evaluation. As a 
result, syndromic cases of CVM may be underestimated. In addition, the traditionally cited 
incidence for CVMs of ~1% of live births likely also underestimates the scope and impact of 
disease. Taking into account very high rates of CVMs in spontaneous abortuses, common 
malformations such as BAV (present in 1.2% of the population) and latent cardiac diseases 
such as aortic dilation which are not included in the birth incidence of CVMs, genetically 
mediated CVMs are likely much more common than previously thought. When considering 
the etiology of CVMs, as opposed to the proportion of CVM cases that manifest as disease 
at birth, the incidence increases to approximately 5%.
Recently, we summarized the overall progress in the molecular genetic analyses of CVMs 
and current recommendations for clinical application of genetic testing. In particular, we 
reviewed the utility and limitations of chromosomal microarray analyses (CMAs) and the 
emerging clinical roles for whole exome sequencing (WES) and other next-generation 
sequencing (NGS) technologies 6. Readers with an interest in the current clinical testing 
approaches for CVMs are referred there. Here, we focus on common genetic and 
developmental themes across the wide variety of CVMs and the ability of animal models 
and knowledge of cardiac developmental biology to impact our understanding and approach 
to CVMs.
The genetic basis of CVMs
Epidemiologic studies suggest that a syndromic form of CVM is identifiable in 
approximately 20% to 30% of cases 4. Known genetic causes are extremely heterogeneous, 
encompassing not only mutations in cardiac relevant genes but also more complex 
chromosomal abnormalities, submicroscopic duplications/deletions, and whole-chromosome 
aneuploidies (Table 1). As noted above, CVMs can be isolated or can occur as part of a well-
recognized genetic syndrome, and this distinction may be subtle.
Inheritance patterns for many CVM-associated genetic conditions are well characterized 
(reviewed in 6) (Table 2). Genetic syndromic conditions associated with CVMs are most 
commonly de novo or autosomal dominant. For dominantly inherited conditions, such as 
Noonan or Holt-Oram syndromes, individual recurrence risks for offspring with the 
syndrome is 50%. Importantly, not all patients with a particular syndrome have associated 
heart defects and the proportion can vary by syndrome. Furthermore, the presence or 
severity of a CVM in the parent does not predict the severity in the child.
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Isolated CVMs may be inherited as autosomal dominant, autosomal recessive, or X-linked 
conditions, but are most commonly sporadic with multifactorial etiology (Table 3). Like 
other conditions inherited as a complex trait, isolated CVMs may show familial clustering 
with reduced penetrance7. For these reasons, recurrence risks for isolated CVMs can be 
difficult to assign. Consistent evidence of high heritability of isolated CVMs indicate that a 
strong genetic component exists, even for defects occurring without an obvious mode of 
inheritance 8.
Gene dosage as a mechanism for CVM
Gene dosage is an important concept underlying genetic disease, including birth defects. For 
many genes, a missing (deletion) or extra (duplication) copy of that gene results in no 
phenotypic consequences. In contrast, dosage sensitive genes produce abnormal phenotypes 
in the absence of two functional genes. Aneuploidies such as Trisomy 21 and Turner 
syndrome demonstrate that proper chromosome number is required for normal development. 
CVMs, including AVSD, are seen in approximately 50% of individuals with Down 
syndrome. Likewise, up to 50% of patients with Turner syndrome will have a CVM, most 
commonly a defect in the left ventricular outflow tract. Because of the large number of 
genes with abnormal dosage in these conditions, identifying the causal genes for the cardiac 
features has proven difficult. Furthermore, the decreased penetrance of the CVMs suggests 
that genetic modifiers interact with dosage-sensitive gene(s) on the same chromosome (in 
the case of Trisomy 21) or other chromosomes to cause CVM. Thus, a threshold exists in 
both aneuploid and euploid populations for the number of genetic perturbations that can be 
tolerated before CVM results. For example, Creld1 and Hey2 were recently identified as 
potential modifier genes in Trisomy 219. Mice with mutant forms of these potential 
modifiers were intercrossed to the Ts65Dn mouse model of Down syndrome. Breeding loss-
of-function alleles of either Creld1 or Hey2 onto the trisomic background causes a 
significant increase in the frequency of CVM. This supports a threshold hypothesis for 
additive effects of genetic modifiers in the sensitized trisomic population.
Submicroscopic chromosome deletions and duplications also underlie many genetic 
syndromes, and the term genomic disorder is used to refer to these conditions. Two classic 
genomic disorders, 22q11.2 deletion syndrome and Williams-Beuren syndrome, are 
discussed in further detail below.
Understanding the genetic basis of syndromic CVM can identify important genes for 
isolated CVM
Williams-Beuren syndrome (WBS) is a relatively common genetic syndrome associated with 
CVM caused by deletion at 7q11.23, resulting in haploinsufficiency of multiple genes, 
including elastin, ELN. Supravalvar aortic stenosis (SVAS) is the most classic cardiac 
finding in WBS, although other defects, including peripheral pulmonic stenosis, occur. 
Subsequent to the description of WBS as a deletion at 7q11.23 in 199310, Ewart et al. 
showed close linkage of ELN and supravalvular aortic stenosis (SVAS) in two families11. 
Deletions or point mutations limited to the ELN gene appear to result in nonsyndromic 
SVAS, whereas larger deletions spanning multiple genes lead to the WBS. Studies in a 
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mouse model with elastin deficiency have successfully corroborated the genetic findings 
with regard to SVAS and latent aortic disease 12, 13.
22q11.2 deletion syndrome provides a second example of a genomic disorder that led to the 
identification of a single gene causing CVM. CVMs occur in approximately 75% of patients 
with 22q11.2 deletion syndrome, with conotruncal defects predominating. After the 
identification of 22q11.2 deletion syndrome, significant effort was put forth to delineate the 
dosage sensitive gene(s) responsible for the CVMs using mouse development and genetics, 
ultimately identifying Tbx114, 15. Yagi et al. investigated TBX1 mutations in families who 
had 22q11.2 deletion syndrome phenotype but no detectable deletion and found that TBX1 
mutations are responsible for many major phenotypes of the syndrome, including CVMs. In 
much the same way that modifiers for the Ts65Dn mouse model of Down syndrome were 
identified, sonic hedgehog and retinoic acid developmental signaling pathways modify the 
phenotypes of a 22q11.2 deletion syndrome mouse model, suggesting that mice with 
reduced gene dosage are sensitized to these morphogens16. These disorders illustrate the 
concept that genes which cause CVMs may be associated with syndromic or isolated 
presentations. Comprehensive identification of dosage sensitive candidate CVM genes and 
integration into an understanding about the genetic and developmental origins of CVM 
would facilitate the development of therapies to rescue the CVMs associated with both 
syndromic and isolated CVM.
Blurring the boundaries: single gene defects that can cause both syndromic and isolated 
CVMs
Genetic testing technologies have identified several genes that cause both syndromic and 
nonsyndromic CVMs (Table 2–3) 6. For example, CVMs, including aortic aneurysm, are 
reported in syndromic patients (i.e., Marfan syndrome (MFS) and Loeys-Dietz syndrome 
(LDS)) with mutations affecting the TGFβ pathway (TGFB2, TGFBR1, TGFBR2, SMAD3, 
FBN1) (Table 2)17, 18. Non-syndromic aortic disease is a frequently asymptomatic but 
potentially lethal disease characterized by familial cases of thoracic aortic aneurysm and 
dissection (FTAAD). This monogenic but genetically heterogeneous condition is primarily 
inherited as an autosomal dominant disorder with variable penetrance and expressivity. 
Mutations in TGFB genes have also been described in nonsyndromic patients with isolated 
CVM or aortic aneurysm (Table 3) 18–21. These facts complicate the clinical approach to 
patients with CVMs and the choice of genetic testing. Furthermore, patients with mutations 
in ACTA2, a gene known to cause isolated FTAAD, can have a syndromic presentation 22 
and pediatric patients with FTAAD frequently have subtle signs of a connective tissue 
disorder 23. As the ability to identify genetic etiology improves, boundaries between 
syndromic and nonsyndromic disease often become less distinct. Careful phenotyping and 
improved interpretation of genetic variation are important to better refine our understanding 
of the spectrum of clinical effects of specific genetic variation.
The developmental basis for CVMs: genes and pathways required for critical stages of 
heart formation
Genetically engineered mice are extensively used in CVM research and have contributed 
greatly to an understanding of the genetic control and mechanistic basis of CVMs. Multiple 
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cell types contribute to the development of a fully septated four-chambered heart, including 
the first heart field (FHF) and second heart field (SHF), cardiac neural crest (NC), epicardial 
(Epi), and endocardial (EC) cell lineages (Fig. 1) 24. Both cardiac NC and endocardium-
derived cushion mesenchyme are important precursors of the outflow tract (OFT) septa and 
semilunar valves25. At embryonic day 9.5 (E9.5), endocardium in the proximal OFT region 
gives rise to cushion mesenchyme via epithelial-mesenchymal transition (EMT) (Fig. 
1) 25, 26. NC cells enter the distal OFT (E10), proliferate, and eventually colonize the 
endocardial ridges of the proximal cushions27. NC cells undergo apoptosis (E11.5 – 13.5), 
and are necessary for aorticopulmonary septation and OFT alignment28. Endocardium-
derived OFT cells also undergo proliferation but remain restricted to the endocardial ridges 
of the proximal OFT cushions (Fig. 2). Remodeling and fusion of the endocardial ridges of 
the proximal cushions results in the formation of fibrous OFT septum that undergoes 
differentiation (E13.5–15.5) and eventually becomes a completely muscular structure 
(E16.5–18.5) through a process called myocardialization26. Despite abundant contributions 
of NC to the OFT mesenchyme, few NC derivatives are present in the mature semilunar 
valves27. Although the precise role of NC cells or their interaction with endocardial EMT-
derived OFT cells remains unclear, more recent studies have suggested that NC cells are also 
important for the remodeling of the semilunar valves 27. Abnormal OFT cushion remodeling 
often results in semilunar valve thickening, defective OFT septation (persistent truncus 
arteriosus, PTA) or alignment defects such as double-outlet right ventricle (DORV) and 
ventricular septal defect (VSD) 25. The signals and cellular events that mediate valve 
remodeling are poorly characterized, although apoptosis and alterations in extracellular 
matrix production have been described 29, 30. Similar developmental events are noted in AV 
cushion formation and remodeling except that the cardiac NC are absent in the AV cushions 
and both dorsal mesocardium and epicardium provides additional cushion components of the 
AV cushion mesenchymal complex (Fig. 2) 31.
Developmental pathways acting independently or in combination contribute to heart 
development and have been reviewed recently 6, 32–34. For example, TGFβ and BMP family 
members play different roles during cardiac development (Fig. 3) (reviewed in 26, 35), and 
mutations in these genes result in distinct phenotypes 35–38. In Loeys-Dietz syndrome 
(LDS), mutations in the TGFβ pathway genes cause thoracic aortic aneurysm (TAA; Table 
3) and are also highly associated with BAV39. Paradoxically, elevated levels of TGFβ1 are 
seen in these patients. Similar increases in TGFβ1 activity is also associated with BAV in 
Turner syndrome 40. Overall, it remains unclear whether the loss-of-TGFB function and/or 
gain-of-TGFB function is the primary cause of CVM. On the other hand, BMP signaling is 
required to induce differentiation of early cardiac progenitors, but BMP signaling is 
inhibited at later stages by Smad6a to permit chamber development mediated by Tbx2 and 
Tbx20. Importantly, the role of a particular signaling pathway can vary as development 
proceeds. For example, Wnt signals are critical for early cardiac precursor induction and 
proliferation, but later become inhibitory. Combinatorial interactions are the rule. Notch 
signaling interacts with both BMP and TGFβ pathways 6, 41. The cardiac transcription factor 
Nkx2.5 physically and functionally interacts with Gata4, Tbx5, and Mef2c, each of which 
forms additional unique and shared connections with other molecular, genetic, and signaling 
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components 6, 33, 34. Such signaling and transcriptional networks hint at the possibility that 
some CVMs may result from additive effects of multiple low-effect susceptibility alleles.
Phenotypic heterogeneity and locus heterogeneity
Studies of gene targeted mouse models indicate that loss of a single gene can result in a 
spectrum of CVMs (Table 4–5, Fig. 4; non-comprehensive examples). For example, the OFT 
malformations of the TGFβ2-deficient fetuses include DORV, PTA, abnormal morphology 
and thickening of aortic and/or pulmonary valves, aortic arch artery malformations (i.e. 
IAA), DILV and/or overriding of tricuspid valves orifice via a perimembranous inlet VSD, 
and abnormal morphology and thickening of tricuspid and mitral valves. Similarly, a range 
of CVM phenotype is seen in mice which lack Tbx1, Nkx2-5, Tbx20, Tbx5, and Gata4.
Different CVM phenotypes are noted in patients with identical mutations, even among 
members of the same family (Table 4). Null mutation in several genes can cause AVSD in 
mice, including Nkx2-5, Gata4, and Tbx1 31. Additional examples are presented in Fig. 4. 
Developmental mechanisms that cause different CVMs in response to a mutation in a single 
gene remain incompletely understood.
Mutations in developmental pathways may result in latent disease
There are numerous potential mechanisms through which genetic mutations could affect the 
complex differentiation and morphogenetic processes in heart development. Once 
developed, the cardiovascular system must undergo homeostasis to maintain function 
throughout life. This ability to repair and remodel following stress and injury uses many of 
the same mechanisms involved in the original development and remodeling of those 
tissues38. Failure of these processes can result in late onset disease. Genes associated with 
CVMs (Fig. 4) 35, 38 are ideal candidates for these homeostatic, stress response and repair 
processes. Improvement in outcomes requires a better understanding of mechanisms 
underlying CVMs and dysregulated homeostatic/repair processes.
There are many interesting examples of genes in which homozygous gene deletion in mice 
results in CVMs in embryos and latent cardiac disease in adult mice, including elastin, 
emilin 1, periostin, and fibrillin 1. Elastin null (Eln−/−) mice die perinatally secondary to 
severe arterial obstruction reminiscent of SVAS12, whereas arteriopathy in the Eln+/− mouse 
manifests as systemic hypertension42. Juvenile Eln+/− mice demonstrate normal valve 
function, but progressive valve disease (predominantly aortic regurgitation) is identified in 
17% of adult and 70% of aged adult Eln+/− mice by echocardiography13. Thus Eln+/− mice 
are a model of latent aortic valve disease and reduced elastin leads to dysregulation in valve 
pathogenesis. Other good examples of mouse models of latent aortic disease include 
Emilin1, Fibrillin-1+/C1039G, and Fibrillin1mgR/mgR (Fbn1mgR/mgR), the latter two being 
mouse models of Marfan syndrome (MFS). The Fbn1mgR/mgR mice die spontaneously from 
rupture of the thoracic aorta between 2 to 4 months of age, and are useful in testing 
therapeutic strategies for aortic aneurysm. On the other hand, Fibrillin-1+/C1039G mice, 
where a point mutation seen in MFS has been made, represent a viable mouse model to 
study the development and progression of aortic aneurysm. The early manifestation of 
elastic fiber fragmentation and aberrant TGFβ signaling suggests that these processes are 
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crucial intermediate factors which provide novel information for diagnosis and treatment of 
patients with aortic disease 23, 43.
Decreased penetrance, variable expressivity and complex inheritance: lessons from 
mouse models
Genetically engineered mice can serve as a useful example of modifying genetic influences 
that affect phenotype. A good example is the different phenotypes seen in Tgfb2 null mice 
on mixed (129/Bl-Swiss) and inbred (C57BL/6) genetic backgrounds. The OFT 
malformations of the inbred null fetuses included DORV (100% cases), PTA (27.2% cases), 
and semilunar valve defects (100% cases). In addition, the null fetuses developed DILV 
and/or overriding of tricuspid valves orifice via a perimembranous inlet VSD (100% cases), 
and tricuspid/mitral valve defects (100%). Notably, the overall penetrance of the observed 
cardiac valve and septal defects was significantly higher in C57BL/6 inbred null fetuses 
compared to Tgfb2 null fetuses on the mixed genetic background. 44 This difference is 
attributed to the differences in genetic modifiers between the strains.
Epigenetic factors in CVM
An increasing recognition of epigenetic factors has revealed an unanticipated breadth to the 
causes of CVMs45. Epigenetics refers to functionally relevant changes to the genome that do 
not involve change in the DNA sequence. DNA methylation and histone modification are 
major epigenetic mechanisms which alter chromatin remodeling and gene expression 
without altering the underlying genetic information 5. A recent study by Pediatric Cardiac 
Genomics Consortium of the NHLBI identified de novo point mutations in several histone 
modifying genes that collectively contribute to approximately 10% of severe CVM5, 21. 
Refinements in technologies such as ChIP-seq and systems biology approaches will aid the 
understanding of global regulation and functional redundancies in cardiac transcription 
factors in CVMs33, 34. MicroRNAs (miRNAs), a class of "small" non-coding RNAs, 
negatively regulate the expression of their target genes through post-transcriptional 
processes and also interact with epigenetic machinery46. Regulation of gene expression via 
mechanisms that affect epigenetic machinery will identify novel etiologies for CVMs.
Future developments
The effect of gene variation on the assembly of distinct cardiac and extracardiac cell 
lineages during heart development is an important area that warrants future investigation. 
The relative importance and role of different cell types in cardiac morphogenesis and 
remodeling remains to be fully understood. Defining gene function in specific cell types in 
mouse models at high resolution will enable predictions to be made about the phenotypic 
consequences of variants in humans that currently lack functional interpretation. 
Experiments that delineate fundamental differences/similarities in loss-of-function and gain-
of-function genetic backgrounds in mice will provide insight into the consequences of gene 
dosage perturbation in humans and mechanisms of genetic disease. Finally, incorporation of 
new technologies such as next generation sequencing, gene expression profiling (i.e., RNA 
seq), and CRISPR/Cas9 -based methodologies to discover and validate novel genes involved 
in CVMs will significantly enhance the understanding of cardiac genetics and development.
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SUMMARY
Cardiac development is a complex, multi-step process under genetic regulation. A detailed 
understanding of the molecular basis of cardiac development is necessary to understand 
disease causation. The field of cardiovascular genetics is progressing at a rapid pace, leading 
to novel diagnostic genetic testing for CVMs. Recent efforts to integrate developmental 
studies from animal models with systems biology approaches offers significant promise for 
future CVM research. Understanding how genetic mutations affect the integration of 
multiple signal transduction pathways to cause CVM is an active area of research. The 
information gained from these developmental and genetic investigations should generate 
novel hypotheses for future experimentation and to provide diagnostic and therapeutic 
avenues for CVM patients.
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KEY POINTS
• There is a strong genetic contribution to cardiovascular malformations 
(CVMs).
• Genes important for syndromic CVM may also cause nonsyndromic 
CVM.
• An understanding of the genes and pathways required for critical stages 
of heart formation informs the approach to genetic testing and 
diagnosis.
• The same gene or genetic locus may cause different types of CVMs 
(phenotypic heterogeneity)
• The same CVM may result from mutations in different genes (locus 
heterogeneity)
• Mouse models are important tools to investigate the complex genetics 
of CVMs.
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Best Practices Box
What is the current practice?
Genetic Testing in Cardiovascular Malformations
• Genetic testing practices for congenital heart defects have yet to be 
standardized in many centers and testing is frequently underutilized.
• Guidelines for cardiac imaging and genetic testing for thoracic aortic 
aneurysm and cardiomyopathy
• A genetic diagnosis has important implications for patient 
management, screening recommendations for family members, and 
recurrence risk counseling
Genetic Testing Options
• Chromosome analysis is the gold standard for diagnosis of aneuploidies 
and other large chromosomal abnormalities.
• Chromosomal microarray (CMA) and fluorescence in situ 
hybridization (FISH) permit identification of microdeletion and 
duplication syndromes resulting from abnormalities too small to be 
detected by conventional chromosome analyses.
• Next generation sequencing (NGS) panels are the test of choice for 
some syndromic congenital heart defects, thoracic aortic aneurysm and 
cardiomyopathy.
• CMA and targeted NGS are non-redundant tests. Consulting a 
geneticist is important for establishing a differential, ordering the 
appropriate test(s), and interpreting results.
Implications for family members
• First degree relatives of patients with specific cardiovascular 
malformations (i.e. left ventricular outflow tract obstructive defects, 
thoracic aortic aneurysm) should undergo cardiac screening
• Family based risk assessment and recurrence risk information differs 
by type of cardiovascular malformation and should be provided to the 
family be a knowledgeable genetics professional.
What changes in current practice are likely to improve outcomes?
• Continued integration of genetic testing services into cardiovascular 
practice will improve diagnostic and prognostic accuracy and will 
support risk assessment and family planning initiatives.
• NGS technologies promise to greatly benefit patient diagnosis and gene 
discovery efforts.
• Appropriate cardiac screening and surveillance in at risk relatives will 
identify latent disease.
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Is there a Clinical Algorithm?
• An algorithm for congenital heart defects has been proposed recently. 6
• Guidelines summarize genetic testing for syndromic and non-
syndromic thoracic aortic aneurysm as well as cardiac screening in first 
degree relatives.47
Major Recommendations
Genetic testing and referral decisions should be determined based on the nature of the 
cardiac defect.
A detailed pedigree should be obtained in all cases of CVM.
Chromosome analysis is recommended for patients with suspected aneuploidy.
Patients with multiple congenital anomalies, neurological findings, developmental delay, 
and/or dysmorphic features should be referred for genetic evaluation.
CMA and/or FISH should be used in patients with conotruncal defects.
Patients with apparently non-syndromic LVOTO, RVOTO, AVSD, heterotaxy, or other 
complex defects should have CMA.
Patients with TAA should have a genetics evaluation and appropriate genetic testing.
Specific CVMs should trigger cardiac screening of first degree relatives.
Rating for the Strength of the Evidence
C Recommendation based on consensus, usual practice, expert opinion, disease-oriented 
evidence, and case series for studies of diagnosis, treatment, prevention, or screening
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Summary
1. Genetic evaluation and testing are increasingly important for 
cardiovascular malformations. Improvements in genetic testing 
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technologies have assisted gene discovery and helped to reshape 
standards of patient care. Risk assessment of family members and 
recurrence risk counseling are important components of management 
and care.
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Figure 1. Diagrammatic representation of heart development
Endocardium (EC) (aqua blue line) forms the endocardial cushions (green circle) via 
cushion EMT (E9.5). Neural crest (NC) (pink circle) cells migrate into the OFT during 
E10.5-12.5. Valve leaflets undergoing differentiation (orange color) and maturation (purple 
color) (E13.5-18.5) are clearly indicated. Only one semilunar valve is shown. SV, semilunar 
valves; AV, atrioventricular canal; RV, right ventricle; LV, left ventricle
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Figure 2. Cardiac remodeling and septation
Myocardium, endocardium, cardiac fibroblasts, and epicardium are major cell types in the 
heart. Left side, Components of OFT and AV cushions are indicated. OFT contains well 
demarcated conal (endocardium-derived) and truncal (NC-derived) cushions. AV cushion 
mesenchymal complex contains superior and inferior AV cushions (predominantly EC-
derived), right and left lateral AV cushions (rlavc, llavc) (with contributions from both 
epicardium and EC), mesenchymal cap (cap) and dorsal mesenchymal protrusion (dmp) 
(dorsal mesocardium-derived). Right side, fully septated 4-chambered heart. The valve 
annulus and vascular wall of the aorta and pulmonary trunk are predominantly comprised of 
smooth muscle cells. Heart valves predominantly contain valve interstitial cells. 
Endocardium/endothelium is the innermost layer, whereas epicardium is the outermost layer. 
Both ventricular and atrial regions contain myocardium and cardiac fibroblasts along with 
coronary vasculature. Purkinje fiber and atrioventricular and sinoatrial nodes constitute the 
cardiac conduction system. AoV, aortic valve; PV, pulmonary valve, RA, right atrium; TV, 
tricuspid valve; RV, right ventricle; LV, left ventricle; MV, mitral valve; LA, left atrium.
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Figure 3. Schematic diagram illustrating the TGFβ signaling pathway
TGFβs binds to a common TGFβ receptor complex, and signals through phosphorylation of 
the canonical TGFβ-specific SMADs (i.e., pSMAD2/3). The pSMAD2/3 forms a complex 
with SMAD4, which accumulates in the nucleus and can regulate target gene expression. 
SMAD4 also binds to BMP-specific SMADs (SMAD1/5/8), and therefore regulates BMP-
target gene expression in heart development.
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Figure 4. Phenotypic and genetic heterogeneity in CVMs
A single genetic abnormality can cause multiply types of CVMs. In addition, the same 
genetic abnormality can result in different CVMs. CVMs are indicated with colored circles.
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Table 1
Causes of Cardiovascular Malformations
Cause Example Characteristic CVMs
Environmental/teratogenic Lithium Chloride Ebstein’s anomaly
Genetic
  Chromosomal Trisomy 21 Atrioventricular canal defect
  Contiguous gene/CNV 22q11.2 deletion syndrome Conotruncal malformations
  Single gene Noonan syndrome Pulmonary valve stenosis
Epigenetic
  DNA methylation De novo SMAD2 mutations Conotruncal malformations
LV obstructions
Heterotaxy
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Table 2
Examples of common syndromes with CVMs caused by single gene mutations
Gene Syndromes
Common cardiac
anomalies
CHD7, SEMA3E CHARGE syndrome ASD, VSD, TOF
FBN1 Marfan syndrome Aortic dilation
JAG1, NOTCH2 Alagille syndrome
PS, peripheral PS,
TOF
KMT2D Kabuki syndrome
ASD, VSD, TOF,
CoA
PTPN11, KRAS,
NRAS, HRAS,
RAF1, SOS1,
NF1, CBL,
BRAF, SHOC2,
MAP2K1,
MAP2K2
Rasopathies: Noonan, Cardiofaciocutaneous, Costello
syndromes PS, HCM
SKI Shprintzen-Goldberg syndrome Aortic dilation
TBX5 Holt-Oram syndrome
ASD, VSD, AVSD,
conduction system
disease
TFAP2b Char syndrome PDA
TGFB2,
TGFBR1,
TGFBR2,
SMAD3 Loeys-Dietz syndrome types 1–4 Aortic dilation
TGFB3 Rheinhoff syndrome Aortic dilation
ZIC3 X-linked heterotaxy syndrome heterotaxy
ASD, atrial septal defect; AVSD, atrioventricular septal defect; CoA, coarctation of the aorta; PDA, patent ductus arteriousus; PS, pulmonic 
stenosis; TOF, tetralogy of Fallot; VSD, ventricular septal defect
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Table 3
Genes causing isolated heart defects
Gene Protein
ETS1 V-Ets avian erythroblastosis virus E26 oncogene homolog 1
TGFB2, TGFB3 Transforming growth factor ligand 2, 3
TGFBR1, TGFBR2 Transforming growth factor receptor 1, 2
SMAD2, SMAD3 Mothers against decapentaplegic, drosophila, homologs 2, 3
HAND1, HAND2 Heart and neural crest derivatives expressed 1, 2
GATA4, GATA5,
GATA6 GATA binding protein 4–6
TBX1 T-box 1
TBX20 T-box 20
CITED2
Cbp/P300-interacting transactivator, with Glu/Asp-rich carboxy-terminal
domain, 2
MESP1 Mesoderm posterior 1 homolog
IRX4 Iroquois homeobox 4
MYOCD Myocardin
Nkx2-5, Nkx2-6 NK2 homeobox 5, 6
NFATC1 Nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1
NOTCH1 Notch1
ELN Elastin
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Table 4
Phenotypic heterogeneity: the same genetic abnormality causes different heart defects
Gene CVMs in genetic mouse models
TGFB2 VSD, TAA, BAV
NKX2-5 VSD, AVSD, ASD
GATA4 ASD, VSD, AVSD
TBX1 AVSD, VSD,
TBX20 VSD, AVSD, ASD
BMP4 VSD, AVSD, ASD
GATA6 VSD, AVSD, ASD
ZIC3
Heterotaxy, d-TGA, DORV, AVSD, other heterotaxy spectrum
heart defects
JAG1 PS, ASD, TOF
GDF1 DORV, TOF, d-TGA
TBX5 ASD, VSD
Trisomy 21 ASD, VSD, PDA
45, X BAV, HLHS, CoA
22q11.2 deletion TOF, VSD, IAA type B
ASD, atrial septal defect; AVSD, atrioventricular septal defect; BAV, bicuspid aortic valve; CoA, coarctation of the aorta; DORV, double outlet right 
ventricle; d-TGA, d-transposition of the great arteries; HLHS, hypoplastic left heart syndrome; IAA, interrupted aortic arch type A; PDA, patent 
ductus arteriousus; PS, pulmonic stenosis; TAA, thoracic aortic aneurysm; TOF, tetralogy of Fallot; VSD, ventricular septal defect
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Table 5
Locus heterogeneity: the same CVM results from distinct genetic loci
CVM Type Examples of genetic etiologies
BAV TGFB signaling pathway single gene mutations, aneuploidy (45,X)
VSD
TGFB and BMP signaling pathway single gene mutations, aneuploidy (45,X;
Trisomy 21), 22q11.2 deletion
DORV GDF1, TBX1, 22q11.2 deletion
AVSD ACVR2, NKX2-5, GATA4, 22q11.2 deletion, aneuploidy (Trisomy 21)
PS JAG1, NOTCH2
TOF JAG1, NOTCH2, 22q11.2 deletion
MVP TGFB2, FBN1, FLNA
TAA TGFB signaling pathway single gene mutations, MYH11, ACTA2, MYLK1, FBN1,
HCM
Rasopathy gene mutations
Sarcomeric gene mutation
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